Market-Moving News for July 10th
$LGVN
$VRPX
$VVPR
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 1/5/2022 | $20.00 | Buy | EF Hutton |
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
PRE 14A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)
6-K - VivoPower International PLC (0001681348) (Filer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
4 - Longeveron Inc. (0001721484) (Issuer)
MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero
GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (N
MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing pharmaceutical products for pain management, announced that it has been granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. This collaboration is for the continued development of Virpax's product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach.
New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceuticals, Inc.'s (NASDAQ:VRPX) successful $5.0 million public offering of common stock and pre-funded warrants. Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company focused on developing novel and proprietary drug delivery systems across various pain indications, raised $5.0 million through the sale of shares of common stock and pre-funded warrants at a public offering price of $0.50 per share. The company intends to use the proceeds for ongoing activities, including its planned Invest
Tembo Tusker is only the 2nd full electric utility vehicle pick up truck to receive full on road homologation VTA regulatory approval in Australia Tuskers can now be driven on road and off road in all states and territories across Australia VTA regulatory approval provides platform for Tembo to accelerate sales and deliveries of Tuskers to customers across all of Australia LONDON, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Tembo E-LV B.V. ("Tembo"), a subsidiary of Nasdaq-listed B Corporation, VivoPower International PLC (NASDAQ:VVPR) ("VivoPower"), is pleased to announce that it has secured full on road homologation vehicle type approval (VTA) for Tembo Tusker 100% electric utility vehicles acr
Spin-off of Caret Digital previously approved by shareholders and subsequently confirmed in December 2023 Caret Digital approached with proposal to mine Dogecoin and Litecoin on its assets, ahead of a potential definitive agreement to enter into reverse merge spin-off with a Canadian counterparty Economics of Dogecoin and Litecoin mining have improved markedly Dogecoin and Litecoin mining use case consistent with Caret Digital's previously announced Power-to-X strategy LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- VivoPower ("the Company") announced today that its Board of Directors has approved an execution plan for its wholly owned subsidiary, Caret Digital, to develop up to 55MW of its
MIAMI, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report third quarter 2024 financial results and provide a business update on Tuesday, November 12, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Details: Conference Call Number:1.877.407.0789Conference ID:13749428 Call me™ Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on the "Events & Presentations" se
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Details: Conference Call Number:1.877.407.0789Conference ID:13747923Call me™ Feature:Click HereWebcast:Click Here An archived replay of the webcast will be available on the "Events & Presentations" sec
EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00
Longeveron's (NYSE:LGVN) short percent of float has fallen 94.31% since its last report. The company recently reported that it has 292 thousand shares sold short, which is 3.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is
Shares of Selective Insurance Group, Inc. (NASDAQ:SIGI) fell sharply during Friday's session following weak quarterly results. Selective Insurance reported quarterly losses of $1.10 per share which missed the analyst consensus estimate of $1.49 per share. The company reported quarterly sales of $1.196 billion which missed the analyst consensus estimate of $1.204 billion, according to data from Benzinga Pro. Selective Insurance Group shares dipped 14.8% to $85.40 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Augmedix, Inc. (NASDAQ:AUGX) shares jumped 148.8% to $2.28 after the company announced it will be acquired by Commure. 60 Degrees Pha
SC 13G/A - Longeveron Inc. (0001721484) (Subject)
SC 13G/A - VivoPower International PLC (0001681348) (Subject)
SC 13G/A - VivoPower International PLC (0001681348) (Subject)